-
公开(公告)号:EP0449897B1
公开(公告)日:1994-02-16
申请号:EP90900763.5
申请日:1989-12-19
申请人: NOVO NORDISK A/S
CPC分类号: C07K14/745
摘要: A pure Factor I protein essentially free of infectious virus, Factor B and C3. The protein is derived from plasma and pasteurized by heating to a temperature of 50 to 65°C for 0.5 to 100 hours in the presence of one or more stabilizers for Factor I. Preparations containing the protein are useful in the treatment of Factor I deficiency and autoimmune diseases.
-
公开(公告)号:EP0401232B1
公开(公告)日:1993-07-21
申请号:EP89901847.7
申请日:1989-01-13
申请人: NOVO NORDISK A/S
发明人: KIHL, Jesper , NYRUP, Allan , NORDFANG, Ole
IPC分类号: A61L2/04 , A61K35/16 , A61K31/725
CPC分类号: A61K38/37 , A61K31/14 , A61L2/0023 , A61L2/04
摘要: In a process for pasteurization of aqueous solutions of Factor VIII, the solution is heated to a temperature of 55-65 DEG C for a period of time of 5-15 hours in the presence of saccharide or a sugar alcohol as well as 1-4, preferably 1.5-2.5 IU of heparin per g of solution. The heparin has a stabilizing effect so that degradation of Factor VIII is avoided or limited.
-
公开(公告)号:EP0449897A1
公开(公告)日:1991-10-09
申请号:EP90900763.0
申请日:1989-12-19
申请人: NOVO NORDISK A/S
CPC分类号: C07K14/745
摘要: La protéine pure de facteur I ne contient pratiquement ni virus infectieux, ni facteur B, ni facteur C3. On pasteurise cette protéine dérivée de plasma en la chauffant jusqu'à une température de 50 à 65°C pendant 0,5 à 100 heures en présence d'un ou plusieurs stabilisateurs du facteur I. Les préparations contenant cette protéine sont utiles pour le traitement des déficiences en facteur I et des maladies auto-immunes.
-
公开(公告)号:EP0401232A1
公开(公告)日:1990-12-12
申请号:EP89901847.0
申请日:1989-01-13
申请人: NOVO NORDISK A/S
发明人: KIHL, Jesper , NYRUP, Allan , NORDFANG, Ole
CPC分类号: A61K38/37 , A61K31/14 , A61L2/0023 , A61L2/04
摘要: In a process for pasteurization of aqueous solutions of Factor VIII, the solution is heated to a temperature of 55-65 DEG C for a period of time of 5-15 hours in the presence of saccharide or a sugar alcohol as well as 1-4, preferably 1.5-2.5 IU of heparin per g of solution. The heparin has a stabilizing effect so that degradation of Factor VIII is avoided or limited.
-
-
-